EVPI and EVPPI for input parameters to the cost-effectiveness model
| Parameters | Individual EVPPI | Population EVPPI* |
| Total EVPI | 123.7 (118, 129.4) | 2 026 008 (1 932 365; 2 119 651) |
| Meta-analysis | 18.75 (3.887, 33.62) | 307 068 (63 655; 550 481) |
| Utilities | 25.97 (11.11, 40.83) | 425 290 (181 877; 668 702) |
| Poststroke disability costs | 20.94 (6.078, 35.81) | 342 953 (99 541; 586 366) |
| Bleed or stroke following cAVR or Ross† | 116.1 (101.2, 130.9) | 1 900 959 (1 657 546; 2 144 372) |
| Other epidemiological parameters‡ | 31.15 (16.28, 46.01) | 510 077 (266 665; 753 490) |
| Ross trial (no costs or utilities)§ | 123.7 (108.9, 138.6) | 2 026 008 (1 782 596; 2 269 421) |
*Population EVPPI given by multiplying individual EVPPI by 8263 population size.
†Early events of stroke or bleed following any of biological AVR, mechAVR or Ross procedure.
‡Other epidemiological parameters are probabilities of disability following stroke; stroke following reoperations for IE on AoV, reoperations for any cause on AoV, reoperations on the pulmonary valve; death following stroke, bleeding events, conservatively treated IE, reoperations for IE on AoV, reoperations for any cause on AoV, reinterventions on the pulmonary valve.
§Ross trial informing all parameters of the meta-analysis, bleed or stroke immediately following cAVR or Ross procedure, and other epidemiological parameters but not costs and utilities.
AoV, aortic valve; EVPI, expected value of perfect information; EVPPI, expected value of partial perfect information; IE, infective endocarditis; biological AVR, tissue aortic valve replacement; cAVR, conventional aortic valve replacement; mechAVR, mechanical aortic valve replacement.